[3] Because the bulk-vial presentation contains detectable aluminum, prolonged use in premature neonates or individuals with impaired renal clearance warrants extreme caution to avoid cumulative neurotoxic exposure
E.TaylorC.PereiraA.SengM.ThamC.-S.IzraelM.et al
Sources: Neelakantan et al., Biochem Pharmacol 2018 | Dimet-Wiley et al., Sci Rep 2024 Security Profile & Chemical Identity Molecular specifications and preclinical safety data 5-Amino-1MQ Chemical Identity A small molecule derived from quinolinium salts, developed at the University of Texas (2017) 5-Amino-1MQ Tolerance & Status Safety data from preclinical studies (DIO mouse model) Published Preclinical Data 3 key studies published in Biochemical Pharmacology and Scientific Reports 35% Reduction of white adipose tissue in 11 days (20 mg/kg, 3 times/day) Physical Effects (11 days) + 40 % Improvement of grip strength in aged mice (22-24 months) Strength & Performance (aged mice) microbiome The combination of 5-Amino-1MQ + caloric restriction establishes a distinct gut microbial profile Protocol & Results Important Notice Search Only Not intended for human consumption
In five multiple-dose studies in healthy subjects (N=82) and in subjects with epilepsy (N=86), when administered under fasting and nonfasting conditions, divalproex sodium extended-release tablets given once daily produced an average bioavailability of 89% relative to an equal total daily dose of divalproex sodium delayed-release tablets given BID, TID, or QID
Remember to subscribe on iTunes and leave a rating
Patients present with mild to severe chronic hemolytic anemia and eventually develop hemochromatosis and its complications, which may be exacerbated by transfusion and coinheritance of other hematopoietic disorders
